Allogeneic transplantation of hematopoietic cells is an effective treatment of leukemia, even
in advanced stages. Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) …

Inducing effective anti-tumor immunity has become a major therapeutic strategy against
cancer. Dendritic cells (DC) are a heterogenous population of antigen presenting cells that …

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in
immunocompromised patients. Patients with hematological malignancies undergoing …

Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

With the manufacture of imatinib, researchers introduced tyrosine kinase inhibitors (TKIs)
into the clinical setting in 2000 to treat cancers; approximately fifteen other TKIs soon …

The tyrosine kinase inhibitor imatinib (imatinib, STI571, Glivec, and Gleevec) is increasingly
used in patients undergoing allogeneic transplantation for leukemia. However, little is known …

Around 15 years ago, imatinib mesylate (Gleevec® or Glivec®, Novartis, Switzerland)
became the very first'targeted'anticancer drug to be clinically approved. This drug constitutes …

Imatinib is a tyrosine kinase inhibitor that suppresses the growth of bcr-abl–expressing
chronic myeloid leukemia (CML) progenitor cells by blockade of the adenosine triphosphate …